| Factor Information | |
|---|---|
| Data ID | 543 |
| Factor | apoferritn levels ng/mL |
| Description | Multivariate analyses determined as risk factors for anemia apoferritn levels below 15 ng/mL (OR, 0.21; 95% CI, 0.09-0.50). Anemia was defined as a condition in which hemoglobin concentration was <13 g/dL in male individuals and <12 g/ dL in female individuals. |
| Biomarker | NA |
| Classification | E2 (physiological factor - biochemical index) |
| Association | |
|---|---|
| Application | prognosis |
| Objective | risk factors for anemia |
| p Value | <0.001 |
| OR | 0.21 |
| Conclusion | The incidence of anemia in CHD patients is similar to that of the normal population and iron deficiency anemia accounts for most of the cases. There were no significant differences in mortality between CHD patients with and without anemia. |
| Risk Factor | protective factor |
| CHD Type | |
|---|---|
| ID | 468 |
| CHD Type | isolated CHD/non-isolated CHD |
| CHD Subtype | ASD/VSD/AVSD/PS/AOS/Bc/CoA/D-TGA/ccTGA/TOF/EA/other |
| Reference | |
|---|---|
| PMID | 29432304 |
| Year | 2018 |
| Title | Anemia in Adolescents and Young Adult Patients With Congenital Heart Disease. |
| Sample | ||
|---|---|---|
| Population | Adolescents and Young Adult | |
| Source | demographic, clinical, and analytic parameters. | |
| Region | Las Palmas de Gran Canaria, Spain | |
| Method | Binary Logistic Regression Analyses | |
| Race | Europe | |
| Disease History | N/A | |
| Treatment History | Aspirin; Oral anticoagulation; Betablockers; ACE ( angiotensin-converting enzyme) inhibitors/ARBs(angiotensin receptor blockers); Diuretics | |
| Group | Anemic CHD patients(Treatment) | Nonanemic CHD patients(Control) |
| Number | 49 | 495 |
| Age | 32 (22-43) years | 30 (22-41) years |
| Gender (Male: Female) | 25:24 | 279:216 |
| Marker Level | 11(6-35) ng/mL | 40(23-74) ng/mL |
